This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

NCT03351244 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

264

Enrollment

INDUSTRY

Sponsor class

Stopped disruption due to COVID-19

Conditions

Schizophrenia

Interventions

DRUG: BI 409306
DRUG: Placebo

Sponsor

Boehringer Ingelheim